BALTIMORE, MD—For more aggressive cases of non-Hodgkin lymphoma (NHL), posttreatment surveillance with molecular imaging could mean the early start of a new, life-saving treatment. This was presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2015 Annual Meeting.
Two new targeted treatments slow progression of chronic-lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma.
New research indicate that malfunctioning genes are only partly to blame for why treatment that was effective ultimately fails in many patients with the most common form of non-Hodgkin lymphoma.
Compared with the vasectomy and control groups, infertile men had a higher risk of testis cancer, non-Hodgkin lymphoma, and all cancers.
Intense physical activity throughout life is linked to a 30 percent reduction in risk.
Level of physical activity over a lifetime can impact risk for non-Hodgkin lymphoma (NHL).
A lower vitamin D levels prior to treatment for follicular lymphoma has been linked to earlier relapse and increased mortality, according to a new study.
Targeting a specific cell survival protein could be key to treating some lymphomas, including those with genetic defects that make them resistant to standard therapies.
Patients with B-cell non-Hodgkin lymphomas and advanced solid tumors have responded to a new drug that is being tested for the first time in humans in a phase I clinical trial.
A new chemotherapy drug being investigated for its potency against two types of cancer was found to be effective in about one-third of the participants in a phase I study.
